Keros Therapeutics (NASDAQ:KROS) Trading Down 5.7% After Analyst Downgrade

Keros Therapeutics, Inc. (NASDAQ:KROS) shares dropped 5.7% during mid-day trading on Tuesday after Oppenheimer lowered their price target on the stock from $102.00 to $63.00. Oppenheimer currently has an outperform rating on the stock. Keros Therapeutics traded as low as $18.12 and last traded at $18.32. Approximately 350,670 shares traded hands during mid-day trading, a decline of 24% from the average daily volume of 463,453 shares. The stock had previously closed at $19.42.

A number of other equities research analysts also recently issued reports on KROS. William Blair downgraded shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 12th. TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Wedbush reaffirmed an “outperform” rating and issued a $84.00 price objective on shares of Keros Therapeutics in a research note on Thursday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Finally, BTIG Research downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $81.33.

Hedge Funds Weigh In On Keros Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in KROS. FMR LLC raised its position in shares of Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after buying an additional 179,374 shares in the last quarter. Alkeon Capital Management LLC raised its position in Keros Therapeutics by 18.7% during the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after purchasing an additional 298,694 shares during the period. Darwin Global Management Ltd. lifted its stake in shares of Keros Therapeutics by 6.3% in the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock valued at $68,772,000 after purchasing an additional 89,952 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after purchasing an additional 577,220 shares during the period. Finally, Holocene Advisors LP raised its position in Keros Therapeutics by 22.5% in the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock worth $48,959,000 after purchasing an additional 154,784 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Stock Down 4.8 %

The company’s 50 day simple moving average is $56.64 and its 200-day simple moving average is $52.06. The firm has a market cap of $693.88 million, a P/E ratio of -3.29 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.33) EPS. Equities research analysts predict that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.